Merck Gets EU Approval for Keytruda Cancer Therapy
Provided by
Dow Jones
By Don Nico Forbes
Merck's Keytruda therapy received approval from the European Union, in combination with antibody-drug Padcev, as a first-line cancer treatment.
The pharmaceutical company said Tuesday that the combination was approved by the European Commission to treat unresectable or metastatic urothelial carcinoma in adults, following a recommendation from the European Society for Medical Oncology and European Association of Urology.
Keytruda is now approved for three indications in bladder cancer, and for 28 indications overall in the EU, Merck said.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
September 03, 2024 07:35 ET (11:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States